Analyst Initiates Coverage on Twist Bioscience (NASDAQ:TWST) with 'Overweight' Rating

• Piper Sandler initiated coverage on Twist Bioscience (NASDAQ:TWST) with an "Overweight" rating, signaling positive future performance in the synthetic biology and genomics sectors.
• Analyst David Westenberg set a price target of $85.00 for Twist Bioscience, indicating a potential 25.42% upside from its trading price of $67.77.
• The company boasts a market capitalization of approximately $4.22 billion and has seen significant stock performance, with a 52-week high of $80.50 and a low of $23.30.

Twist Bioscience (NASDAQ:TWST) is a company in the synthetic biology field, focusing on manufacturing synthetic DNA. It operates in the growing genomics sector, where demand for precision medicine is increasing. This places Twist Bioscience in the spotlight alongside competitors like Pacific Biosciences of California (NASDAQ:PACB) and Myriad Genetics (NASDAQ:MYGN), as highlighted by Zacks Investment Research.

On June 11, 2026, Piper Sandler analyst David Westenberg initiated coverage on Twist Bioscience with an "Overweight" rating. This type of analyst rating suggests that the analyst believes the stock will perform better than the average return of other stocks in its sector over the next 6 to 12 months.

Westenberg also set a price target of $85.00 for the company. A price target is an analyst's projection of a stock's future price. It acts as an estimate of the stock's potential value, which can help investors make informed decisions.

At the time of the rating, Twist Bioscience was trading at $67.77. This price indicates a potential upside, or increase, of 25.42% to reach the new $85.00 target. During the day's trading session, the stock's price has moved between a low of $67.24 and a high of $71.77.

The company currently has a market capitalization of approximately $4.22 billion, which is the total value of all its shares. Over the past 52 weeks, the stock has seen a high of $80.50 and a low of $23.30, with a current trading volume of over 1.14 million shares.